Anti-Inflammatory and Organ-Protective Effects of Resveratrol in Trauma-Hemorrhagic Injury.
Resveratrol, a natural polyphenolic compound of grape and red wine, owns potential anti-inflammatory effects, which results in the reduction of cytokines overproduction, the inhibition of neutrophil activity, and the alteration of adhesion molecules expression. Resveratrol also possesses antioxidant, anti-coagulation and anti-aging properties, and it may control of cell cycle and apoptosis. Resveratrol has been shown to reduce organ damage following traumatic and shock-like states. Such protective phenomenon is reported to be implicated in a variety of intracellular signaling pathways including the activation of estrogen receptor, the regulation of the sirtuin 1/nuclear factor-kappa B and mitogen-activated protein kinases/hemeoxygenase-1 pathway, and the mediation of proinflammatory cytokines and reactive oxygen species formation and reaction. In the recent studies, resveratrol attenuates hepatocyte injury and improves cardiac contractility due to reduction of proinflammatory mediator expression and ameliorates hypoxia-induced liver and kidney mitochondrial dysfunction following trauma and hemorrhagic injuries. Moreover, through anti-inflammatory effects and antioxidant properties, the resveratrol is believed to protect organ function in trauma-hemorrhagic injury. In this review, the organ-protective and anti-inflammatory effects of resveratrol in trauma-hemorrhagic injury will be discussed.
Department of Anesthesiology, Chang Gung Memorial Hospital, Taoyuan City 333, Taiwan ; College of Medicine, Chang Gung University, Taoyuan City 333, Taiwan ; Graduate Institute of Clinical Medical Sciences, Chang Gung University, Taoyuan City 333, Taiwan.
Fu-Chao
FC
Liu
Department of Anesthesiology, Chang Gung Memorial Hospital, Taoyuan City 333, Taiwan ; College of Medicine, Chang Gung University, Taoyuan City 333, Taiwan ; Graduate Institute of Clinical Medical Sciences, Chang Gung University, Taoyuan City 333, Taiwan.
Yung-Fong
YF
Tsai
Department of Anesthesiology, Chang Gung Memorial Hospital, Taoyuan City 333, Taiwan ; College of Medicine, Chang Gung University, Taoyuan City 333, Taiwan ; Graduate Institute of Clinical Medical Sciences, Chang Gung University, Taoyuan City 333, Taiwan.
Hsin-I
HI
Tsai
Department of Anesthesiology, Chang Gung Memorial Hospital, Taoyuan City 333, Taiwan ; College of Medicine, Chang Gung University, Taoyuan City 333, Taiwan.
Huang-Ping
HP
Yu
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000975:Antioxidants / Q000627:therapeutic use*; D006801:Humans; D000077185:Resveratrol; D012771:Shock, Hemorrhagic / Q000188:drug therapy* / Q000378:metabolism; D056564:Sirtuin 1 / Q000378:metabolism; D013267:Stilbenes / Q000627:therapeutic use*; D014947:Wounds and Injuries / Q000188:drug therapy* / Q000378:metabolism
D000893:Anti-Inflammatory Agents; D000975:Antioxidants; D013267:Stilbenes; D056564:Sirtuin 1; D000077185:Resveratrol